至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Characterization of lead compounds targeting the selenoprotein thioredoxin glutathione reductase for treatment of schistosomiasis

ACS Infectious Diseases. 2016-04; 
Haining Lyu; Pavel A. Petukhov; Paul R. Banta; Ajit Jadhav; Wendy A. Lea; Qing Cheng; Elias S. J. Arn r; Anton Simeonov; Gregory R. J. Thatcher; Francesco Angelucci; David L. Williams
Products/Services Used Details Operation

摘要

Schistosomiasis is a widespread human parasitic disease currently affecting over 200 million people. Chemotherapy for schistosomiasis relies exclusively on praziquantel. Although significant advances have been made in recent years to reduce the incidence and intensity of schistosome infections, these gains will be at risk should drug resistance parasites evolve. Thioredoxin glutathione reductase (TGR) is a selenoprotein of the parasite essential for the survival of schistosomes in the mammalian host. Several high-throughput screening campaigns have identified inhibitors of Schistosoma mansoni TGR. Follow up analyses of select active compounds form the basis of the present study. We identified eight compounds ef... More

关键词

drug development, helminth, mechanism of inhibition, neglected disease, redox biology, high throughput screen